A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses

被引:20
|
作者
Schilling, Andrea L. [1 ]
Kulahci, Yalcin [1 ]
Moore, John [2 ]
Wang, Eric W. [2 ]
Lee, Stella E. [2 ]
Little, Steven R. [1 ,3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Pittsburgh, Dept Chem Engn, 940 Benedum Hall,3700 OHara St, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1400 Locust St,Suite 2100, Pittsburgh, PA 15219 USA
[3] Univ Pittsburgh, Dept Bioengn, 302 Benedum Hall,3700 OHara St, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Clin & Translat Sci, Forbes Tower,Suite 7057, Pittsburgh, PA 15213 USA
[5] Univ Pittsburgh, McGowan Inst Regenerat Med, 450 Technol Dr,Suite 300, Pittsburgh, PA 15219 USA
[6] Univ Pittsburgh, Dept Immunol, 200 Lothrop St, Pittsburgh, PA 15213 USA
[7] Univ Pittsburgh, Dept Pharmaceut Sci, 3501 Terrace St, Pittsburgh, PA 15213 USA
基金
美国国家卫生研究院;
关键词
Thermoresponsive; Microsphere; Hydrogel; Sustained release; Steroid; Sinusitis;
D O I
10.1016/j.jconrel.2020.10.062
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Delivering localized treatment to the paranasal sinuses for diseases such as chronic rhinosinusitis (CRS) is particularly challenging because of the small natural openings leading from the sinuses that can be further obstructed by presence of inflammation. As such, oral steroids, topical nasal sprays or irrigation, and surgery can be utilized to treat persistent sinonasal inflammation, but there exists a need for post-operative options for long-term steroid delivery to prevent disease recurrence. In the present study, a Thermogel, Extended-release Microsphere-based-delivery to the Paranasal Sinuses (TEMPS) is developed with the corticosteroid mometasone furoate. Specifically, the bioactive steroid is released for 4 weeks from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a poly(N-isopropylacrylamide) (p-NIPAAm)-based hydrogel. The temperature-responsive system undergoes a reversible sol-gel transition at 34-35 degrees C such that it can be applied as a liquid at ambient temperature, conforming to the sinonasal epithelium as it gels. In a rabbit model of CRS, TEMPS was maintained in rabbit sinuses and effectively reduced sinonasal inflammation as characterized by micro-computed tomography and histopathology analysis. Ultimately, the combination of controlled release microspheres with a thermoresponsive hydrogel provides flexibility for encapsulating therapeutics in a reversible and conforming system for localized delivery to the sinuses.
引用
收藏
页码:889 / 897
页数:9
相关论文
共 50 条
  • [41] Atelocollagen-mediated delivery system for long-acting nucleic acid medicinal therapies
    Nagahara, S
    Ochiya, T
    Sano, A
    Ito, H
    Honma, K
    Terada, M
    MOLECULAR THERAPY, 2003, 7 (05) : S66 - S66
  • [42] INDUCTION OF PARTURITION IN THE COW - THE USE OF A SHORT-ACTING CORTICOSTEROID ALONE OR AT 5 DAYS AFTER AN INJECTION OF A LONG-ACTING CORTICOSTEROID
    DISKIN, MG
    SREENAN, JM
    IRISH VETERINARY JOURNAL, 1984, 38 (01) : 6 - 13
  • [43] Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting 2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 945 - 953
  • [44] ACTION OF A PROGESTOGEN AND A LONG-ACTING CORTICOSTEROID IN CERTAIN CARCINOMAS OF BREAST WITH WIDESPREAD METASTASES
    PROUX, C
    NOUVELLE PRESSE MEDICALE, 1976, 5 (05): : 276 - 276
  • [45] The role of combination inhaled corticosteroid/long-acting β-agonist therapy in COPD management
    Mapel, Douglas W.
    Hurley, Judith S.
    Dalal, Anand A.
    Blanchette, Christopher M.
    PRIMARY CARE RESPIRATORY JOURNAL, 2010, 19 (02): : 93 - 103
  • [46] Corticosteroid and long-acting β-agonist therapy reduces epithelial goblet cell metaplasia
    Lachowicz-Scroggins, M. E.
    Finkbeiner, W. E.
    Gordon, E. D.
    Yuan, S.
    Zlock, L.
    Bhakta, N. R.
    Woodruff, P. G.
    Fahy, J. V.
    Boushey, H. A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2017, 47 (12): : 1534 - 1545
  • [47] Review of inhaled corticosteroid/long-acting beta2-agonist combinations
    Roefaro, John
    Daryanani, Anita A.
    FORMULARY, 2008, 43 (06) : 204 - +
  • [48] Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
    Pavord, Ian D.
    Lettis, Sally
    Locantore, Nicholas
    Pascoe, Steve
    Jones, Paul W.
    Wedzicha, Jadwiga A.
    Barnes, Neil C.
    THORAX, 2016, 71 (02) : 118 - 125
  • [49] Corticosteroid And Long-Acting β-Agonist Therapy Reduces Epithelial Goblet Cell Metaplasia
    Lachowicz-Scroggins, M. E.
    Finkbeiner, W. E.
    Yuan, S.
    Gordon, E. D.
    Zlock, L.
    Bhakta, N. R.
    Woodruff, P. G.
    Fahy, J. V.
    Boushey, H. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [50] The impact of inhaled corticosteroid and long-acting β-agonist combination therapy on outcomes in COPD
    Hanania, Nicola A.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (03) : 540 - 550